Bluejay Diagnostics (BJDX) Share-based Compensation (2020 - 2025)
Bluejay Diagnostics (BJDX) reported Share-based Compensation of $74.0 for Q4 2025, up 100.03% on a YoY basis from $37.0 in Q4 2024, and down 59.56% sequentially from $183.0 in Q3 2025.
Bluejay Diagnostics (BJDX) Share-based Compensation (2020 - 2025) Analysis & Trends
Bluejay Diagnostics (BJDX) has 6 years of Share-based Compensation data on file, last reported at $74.0 in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 100.03% year-over-year to $74.0; the trailing twelve-month figure through Dec 2025 stood at $6.0 (up 100.0% YoY), and the FY2025 full-year result was $6.0, down 99.97% from the prior year.
- Share-based Compensation slipped to $74.0 in Q4 2025, from $183.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $126086.0 in Q1 2022 to a low of -$287469.0 in Q4 2024.
- A 5-year average of $6544.6 and a median of $5401.0 in 2024 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation soared 76781.71% in 2022 and plunged 266.39% in 2023, its largest moves.
- Tracing BJDX's Share-based Compensation over 5 years: stood at $21634.0 in 2021, then jumped by 304.85% to $87586.0 in 2022, then sank by 266.39% to -$145732.0 in 2023, then plunged by 97.26% to -$287469.0 in 2024, then jumped by 100.03% to $74.0 in 2025.
- Business Quant data shows BJDX's Share-based Compensation at $74.0 in Q4 2025, $183.0 in Q3 2025, and -$1563.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 35.80 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 35.12 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 74.00 |
| Dec 31, 2025 | 74.00 |
| Sep 30, 2025 | 183.00 |
| Sep 30, 2025 | 183.00 |
| Jun 30, 2025 | -1,563.00 |
| Jun 30, 2025 | -1,563.00 |
| Mar 31, 2025 | 1,312.00 |
| Mar 31, 2025 | 1,312.00 |
| Dec 31, 2024 | -287,469.00 |
| Dec 31, 2024 | -287,469.00 |
| Sep 30, 2024 | 4,792.00 |
| Sep 30, 2024 | 4,792.00 |
| Jun 30, 2024 | 6,010.00 |
| Jun 30, 2024 | 6,010.00 |
| Mar 31, 2024 | 11,874.00 |
| Mar 31, 2024 | 11,874.00 |
| Dec 31, 2023 | -145,732.00 |
| Dec 31, 2023 | -145,732.00 |
| Sep 30, 2023 | -42,482.00 |
| Sep 30, 2023 | -42,482.00 |